Shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB – Get Free Report) passed below its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $24.56 and traded as low as $22.83. Zai Lab shares last traded at $23.47, with a volume of 735,440 shares trading hands.
Analysts Set New Price Targets
ZLAB has been the topic of several recent analyst reports. Citigroup upped their price target on Zai Lab from $44.00 to $45.00 and gave the company a “buy” rating in a research report on Friday, August 7th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Zai Lab in a research note on Tuesday, October 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Zai Lab in a report on Tuesday, October 27th. Finally, Wall Street Zen raised shares of Zai Lab from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $37.25.
Check Out Our Latest Stock Analysis on Zai Lab
Zai Lab Stock Down 4.6%
The company’s 50-day simple moving average is $24.56 and its 200 day simple moving average is $21.29. The stock has a market capitalization of $2.94 billion, a price-to-earnings ratio of -13.11 and a beta of 0.77.
Zai Lab (NASDAQ:ZLAB – Get Free Report) last released its earnings results on Thursday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.18. The firm had revenue of $108.21 million for the quarter, compared to analyst estimates of $107.90 million. Zai Lab had a negative return on equity of 31.15% and a negative net margin of 44.91%. On average, equities analysts expect that Zai Lab Limited Unsponsored ADR will post -2.19 earnings per share for the current fiscal year.
Insider Buying and Selling at Zai Lab
In other Zai Lab news, Director Richard Gaynor acquired 1,228 shares of Zai Lab stock in a transaction dated Tuesday, November 10th. The stock was bought at an average cost of $27.19 per share, with a total value of $33,389.32. Following the completion of the transaction, the director owned 81,965 shares of the company’s stock, valued at $2,228,628.35. The trade was a 1.52% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 4.88% of the company’s stock.
Hedge Funds Weigh In On Zai Lab
A number of institutional investors and hedge funds have recently bought and sold shares of ZLAB. Soleus Capital Management L.P. bought a new stake in Zai Lab in the 3rd quarter valued at $40,643,000. Toronto Dominion Bank bought a new position in shares of Zai Lab during the 3rd quarter worth about $26,193,000. Nan Fung Trinity HK Ltd. increased its holdings in shares of Zai Lab by 106.9% during the 3rd quarter. Nan Fung Trinity HK Ltd. now owns 293,966 shares of the company’s stock worth $7,743,000 after purchasing an additional 151,883 shares during the period. Nantahala Capital Management LLC raised its position in shares of Zai Lab by 65.0% during the third quarter. Nantahala Capital Management LLC now owns 330,000 shares of the company’s stock valued at $8,692,000 after buying an additional 130,000 shares during the last quarter. Finally, Seven Fleet Capital Management LP raised its position in shares of Zai Lab by 74.7% during the second quarter. Seven Fleet Capital Management LP now owns 136,016 shares of the company’s stock valued at $2,584,000 after buying an additional 58,158 shares during the last quarter. Institutional investors own 41.65% of the company’s stock.
Zai Lab Company Profile
Zai Lab is a biopharmaceutical company that discovers, develops and commercializes medicines for patients with serious diseases. Its research and development programs focus on oncology, immunology, neuroscience and infectious diseases. Founded in 2014 by biopharmaceutical executive Samantha Du, the company is headquartered in Shanghai and operates in China and the United States. It advances its own drug candidates and works with international partners to develop and bring therapies to market. Zai Lab’s portfolio includes medicines and development programs for cancers and other conditions, including therapies introduced through licensing and collaboration agreements.
Featured Articles
- Five stocks we like better than Zai Lab
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Zai Lab Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zai Lab and related companies with MarketBeat.com's FREE daily email newsletter.
